Leap Therapeutics acquires Flame Biosciences through merger deal

17 January 2023
leap_therapeutics_large

Cambridge, Massachusetts-based oncology specialist Leap Therapeutics (Nasdaq: LPTX) has bought the privately-owned company Flame Biosciences.

Leap, which is focused on developing targeted and immuno-oncology therapeutics, will merge with Flame to create a new company which will continue to trade under the LPTX ticker symbol.

The new company will boast pipeline assets including FL-301, a clinical stage anti-Claudin18.2 antibody, FL-302, a pre-clinical anti-Claudin18.2/CD137 bispecific antibody and FL-501, a pre-clinical anti-GDF15 antibody.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology